跳至主要内容
临床试验/NCT05858203
NCT05858203招募中不适用

Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment

Regina Elena Cancer Institute2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年12月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
150
试验地点
2
主要终点
Che-1 involvement in MM tumorigenesis

研究概览

简要总结

Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of proliferating antibody producing plasma cells in the bone marrow. In the last few years many studies have emphasized the biological complexity and heterogeneity of MM as a result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and stress response. it can be hypothesized that Che-1 might contribute to the establishment of the MM malignant phenotype by sustaining global transcription through its ability to modulate chromatin accessibility.

The prospective study on MM human samples aims to understand the involvement of Che-1 in the transcriptional regulation and chromatin remodeling during the pathology. To this goal the main objectives are:

  • Characterization of Che-1's role in chromatin remodeling and global gene expression
  • Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis
  • Evaluation of Che-1 as a possible therapeutic target

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • MM Patients

排除标准

  • No exclusion criteria

结局指标

主要结局

Che-1 involvement in MM tumorigenesis

时间窗: About 2 years

Characterization of Che-1's role in chromatin remodeling and global gene expression

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验